<?xml version="1.0" encoding="UTF-8"?>
<paload id="uuid-here" version="1.0">
    <toplevel>
        <routedMedId>154218</routedMedId>
        <routedMedName>Prolia subcutaneous</routedMedName>
        <routedGenericName>denosumab subcutaneous</routedGenericName>
        <etcIds>
            <etc_id>6239</etc_id>
        </etcIds>
        <medIds>
            <medId>561413</medId>
        </medIds>
    </toplevel>
    <diagnoses>
        <diagnosis>
            <fqn>Osteoporosis with high risk of fracture (female member)</fqn>
            <icd9>2896</icd9>
            <symbolic>ostfemale</symbolic>
            <rating>labeledDx</rating>
            <genotype/>
            <subtype>
                <name>high risk of fracture</name>
                <dur/>
                <durUnit/>
            </subtype>
            <prescribers>
                <prescriber>
                    <name>Not Appicable</name>
                    <code>Not Applicable</code>
                </prescriber>
            </prescribers>
            <age>Greater than 18 years</age>
            <triedtherapy>
                <criteriaSet>
                    <patientHxType>
                        <typeName>any</typeName>
                        <treatment/>
                    </patientHxType>
                    <preferredTherapy>
                        <treatment>
                            <treatmentLine>
                                <ineligibilityFlag>true</ineligibilityFlag>
                                <option>OR</option>
                                <interventionType>group</interventionType>
                                <codeValues>01.1265|01.15387|01.1249|01.124640|01.197285|01.79194|01.79193|01.113876|01.7510|01.20382|01.113840|01.20384</codeValues>
                                <selectedListName>Bone Resorption Inhibitors - Bisphosphonates</selectedListName>
                                <selectedListClassCode>01.176</selectedListClassCode>
                                <dur/>
                                <durUnit/>
                                <durModifier/>
                                <timeframe>no timeframe specified</timeframe>
                                <numRequired>any</numRequired>
                            </treatmentLine>
                            <treatmentLine>
                                <ineligibilityFlag>false</ineligibilityFlag>
                                <option>OR</option>
                                <interventionType>group</interventionType>
                                <codeValues>01.1265|01.15387|01.1249|01.124640|01.197285|01.79194|01.79193|01.113876|01.7510|01.20382|01.113840|01.20384</codeValues>
                                <selectedListName>Bone Resorption Inhibitors - Bisphosphonates</selectedListName>
                                <selectedListClassCode>01.176</selectedListClassCode>
                                <dur>12</dur>
                                <durUnit>months</durUnit>
                                <durModifier>at least</durModifier>
                                <timeframe>no timeframe specified</timeframe>
                                <numRequired>any 2</numRequired>
                            </treatmentLine>
                        </treatment>
                        <numRequired>any</numRequired>
                    </preferredTherapy>
                </criteriaSet>
            </triedtherapy>
            <dosing>
                <text>60 mg subcutaneously once every 6 months</text>
            </dosing>
            <instructions>
                <instruction/>
            </instructions>
            <qlimits>
                <qlimit>
                    <medid>561413</medid>
                    <initPerDayDesc>Not Specified</initPerDayDesc>
                    <initPerIntervalDesc>60mg per 6 months (1 injection per 6 months)</initPerIntervalDesc>
                    <renewPerDayDesc>Not Specified</renewPerDayDesc>
                    <renewPerIntervalDesc>60mg per 6 months (1 injection per 6 months)</renewPerIntervalDesc>
                </qlimit>
            </qlimits>
            <durations>
                <initialDur>
                    <dur>12</dur>
                    <durUnit>months</durUnit>
                </initialDur>
                <renewalDur>
                    <dur>12</dur>
                    <durUnit>months</durUnit>
                </renewalDur>
                <overallMax>
                    <dur/>
                    <durUnit/>
                </overallMax>
            </durations>
            <references>
                <reference>
                    <indicationName/>
                    <indicationCode/>
                    <citation/>
                </reference>
            </references>
            <exclusions/>
            <precautions>
                <precaution>
                    <text/>
                    <severity/>
                </precaution>
            </precautions>
        </diagnosis>
        <diagnosis>
            <fqn>Osteoporosis with high risk of fracture (male member)</fqn>
            <icd9>2896</icd9>
            <symbolic>ostmale</symbolic>
            <rating>labeledDx</rating>
            <genotype/>
            <subtype>
                <name>high risk of fracture</name>
                <dur/>
                <durUnit/>
            </subtype>
            <prescribers>
                <prescriber>
                    <name>Not Appicable</name>
                    <code>Not Applicable</code>
                </prescriber>
            </prescribers>
            <age>Greater than 18 years</age>
            <triedtherapy>
                <criteriaSet>
                    <patientHxType>
                        <typeName>any</typeName>
                        <treatment/>
                    </patientHxType>
                    <preferredTherapy>
                        <treatment>
                            <treatmentLine>
                                <ineligibilityFlag>true</ineligibilityFlag>
                                <option>OR</option>
                                <interventionType>group</interventionType>
                                <codeValues>01.1265|01.15387|01.1249|01.124640|01.197285|01.79194|01.79193|01.113876|01.7510|01.20382|01.113840|01.20384</codeValues>
                                <selectedListName>Bone Resorption Inhibitors - Bisphosphonates</selectedListName>
                                <selectedListClassCode>01.176</selectedListClassCode>
                                <dur/>
                                <durUnit/>
                                <durModifier/>
                                <timeframe>no timeframe specified</timeframe>
                                <numRequired>any</numRequired>
                            </treatmentLine>
                            <treatmentLine>
                                <ineligibilityFlag>false</ineligibilityFlag>
                                <option>OR</option>
                                <interventionType>group</interventionType>
                                <codeValues>01.1265|01.15387|01.1249|01.124640|01.197285|01.79194|01.79193|01.113876|01.7510|01.20382|01.113840|01.20384</codeValues>
                                <selectedListName>Bone Resorption Inhibitors - Bisphosphonates</selectedListName>
                                <selectedListClassCode>01.176</selectedListClassCode>
                                <dur>12</dur>
                                <durUnit>months</durUnit>
                                <durModifier>at least</durModifier>
                                <timeframe>no timeframe specified</timeframe>
                                <numRequired>any 2</numRequired>
                            </treatmentLine>
                        </treatment>
                        <numRequired>any</numRequired>
                    </preferredTherapy>
                </criteriaSet>
            </triedtherapy>
            <dosing>
                <text>60 mg subcutaneously once every 6 months</text>
            </dosing>
            <instructions>
                <instruction/>
            </instructions>
            <qlimits>
                <qlimit>
                    <medid>561413</medid>
                    <initPerDayDesc>Not Specified</initPerDayDesc>
                    <initPerIntervalDesc>60mg per 6 months (1 injection per 6 months)</initPerIntervalDesc>
                    <renewPerDayDesc>Not Specified</renewPerDayDesc>
                    <renewPerIntervalDesc>60mg per 6 months (1 injection per 6 months)</renewPerIntervalDesc>
                </qlimit>
            </qlimits>
            <durations>
                <initialDur>
                    <dur>12</dur>
                    <durUnit>months</durUnit>
                </initialDur>
                <renewalDur>
                    <dur>12</dur>
                    <durUnit>months</durUnit>
                </renewalDur>
                <overallMax>
                    <dur/>
                    <durUnit/>
                </overallMax>
            </durations>
            <references>
                <reference>
                    <indicationName/>
                    <indicationCode/>
                    <citation/>
                </reference>
            </references>
            <exclusions/>
            <precautions>
                <precaution>
                    <text/>
                    <severity/>
                </precaution>
            </precautions>
        </diagnosis>
        <diagnosis>
            <fqn>Long term (current) use of aromatase inhibitors/Malignant neoplasm of breast</fqn>
            <icd9>Z79.811</icd9>
            <symbolic>neobreast</symbolic>
            <rating>labeledDx</rating>
            <genotype/>
            <subtype>
                <name/>
                <dur/>
                <durUnit/>
            </subtype>
            <prescribers>
            </prescribers>
            <age>Greater than 18 years</age>
            <comorbidity>
                <name>Malignant neoplasm of breast</name>
                <icd9>C50</icd9>
                <dur/>
                <durUnit/>
            </comorbidity>
            <triedtherapy>
            </triedtherapy>
            <dosing>
                <text>60 mg subcutaneously once every 6 months</text>
            </dosing>
            <instructions>
                <instruction/>
            </instructions>
            <qlimits>
                <qlimit>
                    <medid>561413</medid>
                    <initPerDayDesc>Not Specified</initPerDayDesc>
                    <initPerIntervalDesc>60mg per 6 months (1 injection per 6 months)</initPerIntervalDesc>
                    <renewPerDayDesc>Not Specified</renewPerDayDesc>
                    <renewPerIntervalDesc>60mg per 6 months (1 injection per 6 months)</renewPerIntervalDesc>
                </qlimit>
            </qlimits>
            <durations>
                <initialDur>
                    <dur>12</dur>
                    <durUnit>months</durUnit>
                </initialDur>
                <renewalDur>
                    <dur>12</dur>
                    <durUnit>months</durUnit>
                </renewalDur>
                <overallMax>
                    <dur/>
                    <durUnit/>
                </overallMax>
            </durations>
            <references>
                <reference>
                    <indicationName/>
                    <indicationCode/>
                    <citation>National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. http://nof.org/files/nof/public/content/file/2610/upload/895.pdf. Published April 1, 2014. Accessed August 1, 2014.</citation>
                </reference>
                <reference>
                    <indicationName/>
                    <indicationCode/>
                    <citation>Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:1802-22. (Also available on the Endocrine Society’s website http://www.endo-society.org/guidelines/Current-Clinical-Practice-Guidelines.cfm)</citation>
                </reference>
                <reference>
                    <indicationName/>
                    <indicationCode/>
                    <citation>Kanis JA; World Health Organization Scientific Group. Assessment of osteoporosis at the primary health care level. http://www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf. Published 2007.  Accessed August 1, 2014.
 </citation>
                </reference>
            </references>
            <exclusions/>
            <precautions>
                <precaution>
                    <text/>
                    <severity/>
                </precaution>
            </precautions>
        </diagnosis>
        <diagnosis>
            <fqn>Bone Loss Secondary to Cancer Treatment/Malignant neoplasm of prostate</fqn>
            <icd9/>
            <symbolic>neoprostate</symbolic>
            <rating>labeledDx</rating>
            <genotype/>
            <subtype>
                <name/>
                <dur/>
                <durUnit/>
            </subtype>
            <prescribers>
            </prescribers>
            <age>Greater than 18 years</age>
            <comorbidity>
                <name>Malignant neoplasm of prostate</name>
                <icd9>C61</icd9>
                <dur/>
                <durUnit/>
            </comorbidity>
            <triedtherapy>
            </triedtherapy>
            <dosing>
                <text>60 mg subcutaneously once every 6 months</text>
            </dosing>
            <instructions>
                <instruction/>
            </instructions>
            <qlimits>
                <qlimit>
                    <medid>561413</medid>
                    <initPerDayDesc>Not Specified</initPerDayDesc>
                    <initPerIntervalDesc>60mg per 6 months (1 injection per 6 months)</initPerIntervalDesc>
                    <renewPerDayDesc>Not Specified</renewPerDayDesc>
                    <renewPerIntervalDesc>60mg per 6 months (1 injection per 6 months)</renewPerIntervalDesc>
                </qlimit>
            </qlimits>
            <durations>
                <initialDur>
                    <dur>12</dur>
                    <durUnit>months</durUnit>
                </initialDur>
                <renewalDur>
                    <dur>12</dur>
                    <durUnit>months</durUnit>
                </renewalDur>
                <overallMax>
                    <dur/>
                    <durUnit/>
                </overallMax>
            </durations>
            <references>
                <reference>
                    <indicationName/>
                    <indicationCode/>
                    <citation/>
                </reference>
            </references>
            <exclusions/>
            <precautions>
                <precaution>
                    <text/>
                    <severity/>
                </precaution>
            </precautions>
        </diagnosis>
    </diagnoses>
    <precautions>
    </precautions>
    <lists>
        <listDef>
            <name>Bone Resorption Inhibitors - Bisphosphonates</name>
            <codeValue>01.176</codeValue>
            <listType>drugclass</listType>
            <listItem>
                <name>Fosamax</name>
                <codeValue>01.1265</codeValue>
            </listItem>
            <listItem>
                <name>risedronate</name>
                <codeValue>01.7510</codeValue>
            </listItem>
            <listItem>
                <name>alendronate</name>
                <codeValue>01.1249</codeValue>
            </listItem>
            <listItem>
                <name>Actonel</name>
                <codeValue>01.15387</codeValue>
            </listItem>
            <listItem>
                <name>zoledronic acid</name>
                <codeValue>01.20382</codeValue>
            </listItem>
            <listItem>
                <name>Zometa</name>
                <codeValue>01.20384</codeValue>
            </listItem>
            <listItem>
                <name>ibandronate</name>
                <codeValue>01.79193</codeValue>
            </listItem>
            <listItem>
                <name>zoledronic acid-mannitol-water</name>
                <codeValue>01.113840</codeValue>
            </listItem>
            <listItem>
                <name>Boniva</name>
                <codeValue>01.79194</codeValue>
            </listItem>
            <listItem>
                <name>Reclast</name>
                <codeValue>01.113876</codeValue>
            </listItem>
            <listItem>
                <name>Atelvia</name>
                <codeValue>01.124640</codeValue>
            </listItem>
            <listItem>
                <name>Binosto</name>
                <codeValue>01.197285</codeValue>
            </listItem>
        </listDef>
    </lists>
</paload>
